This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. To the Editor.— Transderm-V (scopolamine) has recently been marketed in the United States as a treatment for motion sickness. It is a 2.5-cm-square, plastic disk with an adhesive surface that is placed on the skin behind the ear, where it releases 0.5 mg of scopolamine into the systemic circulation during a three-day period. Scopolamine and other cholinergic blocking agents have long been known to produce bothersome adverse effects such as mydriasis, dry mouth, drowsiness, urinary retention, constipation, and a toxic psychosis manifested as delirium, hallucinations, restlessness, and excitability. For this reason, scopolamine, despite its superior efficacy in preventing motion sickness, has been little used in comparison with the antiemetic antihistamines. The transdermal administration of scopolamine, however, has been reported to obviate most of the untoward effects. Drowsiness and dryness of the mouth are noted frequently, but few or no problems have been reported with the other effects. Report of a